FDA Calendar for Acadia Pharmaceuticals Inc (ACAD)

| Register (free)
Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system disorders. The Company is developing a portfolio consisting of its four product candidates, including pimavanserin, which is in Phase III development for the treatment of Parkinson’s disease psychosis. In addition, the Company has a product candidate in Phase II for chronic pain and a product candidate in Phase I for glaucoma, both in collaboration with Allergan, Inc., and ACP-106 in IND-track development. The Company’s product candidates include Pimavanserin, AGN-XX/YY, AC-262271 and ACP-106. The Company maintains two wholly owned subsidiaries: ACADIA Pharmaceuticals AB based in Malmo, Sweden and ACADIA Pharmaceuticals A/S based in Denmark.


Drug Pipeline

Drug NameType Of DrugFDA StatusDrug Phase
This company currently does not have any drugs. If you would like to create one please click here.


Events

No future events listed at this time, please check back later.

Add New Event

In order to write a comment you must first login.

Login or Register (for free!)

Add Event

ACAD

$1.77
0.03 +1.72%
2/3/2012 3:59:00 PM

Sponsors

Other Links